We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals
News

OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals

OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals
News

OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

OSI Pharmaceuticals, Inc. has announced that it has completed its acquisition of Eyetech Pharmaceuticals, Inc.

OSI acquired Eyetech for approximately $685 million in cash and approximately 5.7 million shares of OSI's common stock.

Net of Eyetech's cash and net operating loss carryforwards, OSI valued the acquisition at approximately $650 million.

Eyetech stockholders will receive $15 per share in cash and 0.12275 of OSI shares for each share of Eyetech owned as of the closing date.

The transaction creates a company that focuses on three therapeutic disease areas of significant market potential: oncology, eye diseases and diabetes, and effectively leverages the Company's core expertise in drug discovery and development.

The Company now has two major marketed products (for the treatment of cancer and age-related macular degeneration) and a product pipeline offering both indications for the marketed products and therapeutics in all three disease areas.

Tarceva® and Macugen® are two of the exciting biotech products launched in recent years.

Tarceva, OSI's flagship product, is approved in the United States for the treatment of advanced non-small cell lung cancer (NSCLC) and pancreatic cancer and approved in the European Union for advanced NSCLC.

Macugen is approved in the United States for the treatment of neovascular age-related macular degeneration and European approval is anticipated by year end.

Advertisement